Bod Australia has enrolled the first patients for a UK-based open-label clinical trial exploring the effectiveness of its MediCabilis CBD 5% product in treating symptoms associated with long Covid.
Patients with the condition suffer ongoing or new symptoms that develop in the eight weeks following an initial Covid-19 infection including shortness of breath, fatigue, chest discomfort, loss of concentration, chronic pain, anxiety and insomnia.
Bod said many of these are amenable to treatment with cannabis-based medicines, highlighting the firm’s “significant near-term opportunity”.
Globally, it is estimated that more than half of the 236 million people who have been diagnosed with Covid since December 2019 will develop long Covid.
Led by principal investigator Dr Elizabeth Iverson in collaboration with Drug Science UK, the study aims to recruit 30 participants over the age of 18 that are suffering from the condition.
The first participants are registered patients of the Nimbuscare network of GP practices located around the English city of York, with Drug Science UK continuing to enrol others from within the network.
Under a clinical trial setting, each will be given MediCabilis daily over six months and self-report responses to common long-Covid symptoms via a dedicated smartphone app.
The results will determine the feasibility and safety of Bod’s product in treating the condition, leading, the firm said, to potential commercial partnerships with “large pharmaceutical partners or other corporates”.
Drug Science UK was founded in 2010 as a charity focused on providing an evidence base for sensible and effective drug laws.
Bod CEO Jo Patterson said the development was a major milestone for the company.
She added: “We already have data that supports the use of MediCabilis for the alleviation of a number of long-Covid symptoms and look forward to building this out further so that our medicine can be used for another emerging need state.”